This post was originally published on this site According to a review study published in Frontiers in Pharmacology, dietary plant-based molecules that possess antioxidant properties called polyphenols can aid in the management of benign prostatic hyperplasia (BPH). However, these compounds cannot replace the need for existing therapies, surgical or pharmacological, as an effective treatment of this condition.…
This post was originally published on this site SciFluor Life Sciences announced that an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) is now in effect for SF0166 Topical Ophthalmic Solution, enabling the company to begin clinical trials in patients with wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Allied Minds’…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) approved Adlyxin (lixisenatide) as a new treatment for type 2 diabetes this week. The treatment consists of a daily injection that, combined with diet and exercise, can control blood sugar levels in adults with this common type of diabetes. Adlyxin is a…
This post was originally published on this site Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition usually associated with a poor prognosis. Dana-Farber Cancer Institute researchers tested the effects of a new treatment approach using repeated doses of the immunotherapy drug Yervoy…
This post was originally published on this site AstraZeneca is presenting a broad selection of its novel respiratory disease medicines through more than 60 abstracts and scientific presentations at the American Thoracic Society (ATS) 2016 International Conference through May 18 in San Francisco, Calif. Presentations highlight combinations, respiratory biologics, and scientific research projects that target new…
This post was originally published on this site Radiotherapy after breast cancer surgery that’s limited to former tumor sites is just as effective in treating early cancers as whole breast radiation and has fewer long-term side effects, according to results of a clinical study presented at the recent 10th European Breast Cancer Conference. The trial, called IMPORT LOW and supported…
This post was originally published on this site Elotuzumab in combination with bortezomib and dexamethasone prolongs the progression free survival of patients with relapsed or refractory multiple myeloma (RRMM), according to the study “Randomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) versus Bd for relapsed/refractory multiple myeloma,” recently published in Blood. Current choices of care for the treatment…
This post was originally published on this site A three-drug combination that includes thalidomide, in place of cyclophosphamide, prior to an autologous stem cell transplant was seen to improve response rates in multiple myeloma patients, according to the conclusions of a randomized, open-label Phase 3 trial, titled “VTD is superior to VCD prior to intensive therapy in multiple…
This post was originally published on this site The U.S. Food and Drug Administration has designated Darzalex (daratumumab), in combination with standard-of-care regimens, a breakthrough therapy for people with previously treated multiple myeloma (MM), speeding its clinical development and regulatory review for these patients. The FDA designation is reserved for treatments showing early evidence in clinical studies of substantial improvement over existing therapies. Darzalex…
This post was originally published on this site A randomized Phase 3 clincal trial has concluded that combining bortezomib (Velcade) with pegylated liposomal doxorubicin (PLD) does not show benefit in treating relapsed or refractory multiple myeloma (MM) patients, compared to bortezomib alone. The data was published in Cancer under the title “Final overall survival results of a randomized…
